Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy in Participants With Advanced Malignancies

Trial Profile

A Phase 1 Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy in Participants With Advanced Malignancies

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AB 122 (Primary) ; AB 154 (Primary)
  • Indications Advanced breast cancer; Bladder cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Head and neck cancer; Malignant melanoma; Merkel cell carcinoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Renal cell carcinoma; Squamous cell cancer
  • Focus Adverse reactions
  • Sponsors Arcus Biosciences
  • Most Recent Events

    • 22 Nov 2019 Planned End Date changed from 15 Feb 2020 to 15 Dec 2020.
    • 22 Nov 2019 Planned primary completion date changed from 31 Oct 2019 to 31 Jul 2020.
    • 06 Aug 2019 According to an Arcus Biosciences media release, Company anticipates to report preliminary safety and PK/PD data from the Phase 1 safety dose-escalation and initiate an expansion study in combination with AB122 in NSCLC in 2H 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top